Hot Stocks: Brokerages on Orchid Pharma, D-Mart, NOCIL and Chola Investment
Orchid Pharma with a buy rating, Prabhudas Lilladher has a buy rating on DMart, and a reduce rating on NOCIL. Motilal Oswal maintained a buy rating on Cholamandalam Investment & Finance Ltd.
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Investec on Orchid Pharma: Buy| Target Rs 800
Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800.
The company is set for strong growth over the next 3 years.
The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).
The company believes multiple optionalities can potentially propel it into a different orbit if all goes well.
Motilal Oswal on Cholamandalam Investment & Finance Ltd: Buy| Target Rs 1420
Motilal Oswal maintained a buy rating on Cholamandalam Investment & Finance Ltd with a target price of Rs 1420.
Cholamandalam Finance (CIFC) has taken a successful leap forward in reducing the cyclicality, which was inherent in its core vehicle financing business
CIFC will continue to grow faster than its peers over the medium term, aided by a diversified product suite and a gradual improvement in market share.
Given its focus on diversification, CIFC could enter new retail product segments in the near-to-medium term.
Prabhudas Lilladher on D-Mart: Buy| Target Rs 4724
Prabhudas Lilladher maintained a buy rating on D-Mart with a target price of Rs 4724.
